NDA 021887 · Haleon US Holdings
Alli
Orlistat · Oral · Intestinal Lipase Inhibitor
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Feb 7, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
65
3 Phase 3, 1 recruiting
FAERS reports
23,511
4,652 serious, 118 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 18, 2026.
Use for weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie and low-fat diet
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ALLI · ORLISTAT 60MG · CAPSULE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Orlistat" as an intervention, any sponsor and status, largest first.
- Multifactorial Intervention on Diabetes (MIDiab Study)Pivotal-lookingStatus unknown
Shandong Provincial HospitalGovernment (non-federal)
NCT03430284 · 6,300 participants (planned) · Start Apr 1, 2018 · Primary completion Dec 31, 2021
Drug: Pharmacotherapy · For: Diabetes Mellitus, Type 2
Sites: Jinan, China · 2 sites in all
- Evaluation of Orlistat as Adjuvant Treatment of Obesity in AdultsPivotal-lookingCompleted
EMSIndustry
NCT01755676 · 638 participants · Start Sep 2016 · Primary completion Dec 2017
Drug: Orlistat 60 mg · For: Obesity
Sites: Porto Alegre, Brazil; Campinas, Brazil; Jaú, Brazil · 5 sites in all
- Efficacy and Safety of ATL-962 in Obese DiabeticsPivotal-lookingCompleted
AlizymeIndustry
NCT00156897 · 600 participants · Start Dec 2004
Drug: ATL-962; Orlistat · For: Non-Insulin-Dependent Diabetes Mellitus; Obesity
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 37 sites in all
- The Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00422058 · 564 participants · Start Jan 10, 2007 · Primary completion Sep 13, 2007
Drug: liraglutide; orlistat and 1 more · For: Metabolism and Nutrition Disorder; Obesity
Sites: Edegem, Belgium; Prague, Czechia; Århus C, Denmark · 19 sites in all
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05579249 · 500 participants · Start Jan 19, 2023 · Primary completion Nov 27, 2024
Drug: Semaglutide; Orlistat and 3 more · For: Obesity
Sites: Loma Linda, California
- Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00533481 · 497 participants · Start Feb 2004 · Primary completion Dec 2004
Drug: MK0557 · For: Obesity
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese SubjectsPivotal-lookingCompleted
ShionogiIndustry
NCT01126970 · 486 participants · Start Apr 2010 · Primary completion Jan 2011
Drug: Velneperit 400 mg; Orlistat 120 mg and 2 more · For: Obesity
Sites: Santa Rosa, California; Waterbury, Connecticut; Clearwater, Florida · 25 sites in all
- LOSS- Louisiana Obese Subjects StudyPivotal-lookingTerminated
Pennington Biomedical Research CenterAcademic, hospital or other
NCT00115063 · 390 participants · Start Jul 2005 · Primary completion Dec 2007
Drug: sibutramine, orlistat, diethylpropion · For: Obesity
Sites: Baton Rouge, Louisiana
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,394
- rectal discharge2,422
- gastrointestinal disorder2,153
- constipation1,916
- diarrhoea1,825
- weight increased1,821
- flatulence1,589
- steatorrhoea1,579
- abdominal pain upper1,293
- headache1,023
- abdominal distension975
- nausea835
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 42 |
| 2006 | 31 |
| 2007 | 7,978 |
| 2008 | 5,952 |
| 2009 | 602 |
| 2010 | 493 |
| 2011 | 290 |
| 2012 | 177 |
| 2013 | 122 |
| 2014 | 1,177 |
| 2015 | 1,801 |
| 2016 | 669 |
| 2017 | 673 |
| 2018 | 660 |
| 2019 | 577 |
| 2020 | 497 |
| 2021 | 428 |
| 2022 | 201 |
| 2023 | 340 |
| 2024 | 315 |
| 2025 | 260 |
| 2026 | 197 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
McGowan B, Ciudin A, Baker JL, et al. · Nat Med 2025 · Systematic Review, Network Meta-Analysis
- Orlistat.
McNeely W, Benfield P · Drugs 1998 · Clinical Trial, Controlled Clinical Trial
- Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up.
Franz MJ, VanWormer JJ, Crain AL, et al. · J Am Diet Assoc 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- Obesity in adults.
Delaet D, Schauer D · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Haleon US Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.